{
  "url": "https://openlegislation.uk/human-medicines-regulations-2012/regulation-179",
  "json_url": "https://openlegislation.uk/human-medicines-regulations-2012/regulation-179.json",
  "legislation": "uksi/2012/1916",
  "legislation_title": "The Human Medicines Regulations 2012",
  "legislation_url": "https://openlegislation.uk/human-medicines-regulations-2012",
  "path": "regulation/179",
  "kind": "regulation",
  "number": "179",
  "heading": "Obligation on licensing authority to operate pharmacovigilance system",
  "text": "(1) The licensing authority must operate a pharmacovigilance system in relation to medicinal products for sale or supply in Great Britain.\n(1A) The licensing authority must operate a pharmacovigilance system in relation to medicinal products for sale or supply in Northern Ireland.\n(2) Each pharmacovigilance system must in particular enable the collection of information on the risks that medicinal products present to patients' health or public health, including information on—\n(a) adverse reactions in humans arising from use of a medicinal product (irrespective of whether the use was within the terms of an authorisation or registration); and\n(b) adverse reactions associated with occupational exposure.\n(3) The licensing authority must on an ongoing basis—\n(a) evaluate scientifically the information collected under each pharmacovigilance system;\n(b) consider options for minimising and preventing risks presented by medicinal products; and\n(c) take appropriate regulatory action, if any.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "F",
      "label": "F1",
      "text": "Words in reg. 179(1) inserted (31.12.2020) by S.I. 2019/775, reg. 139A(a) (as inserted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 108)"
    },
    {
      "type": "F",
      "label": "F2",
      "text": "Reg. 179(1A) inserted (31.12.2020) by S.I. 2019/775, reg. 139A(b) (as inserted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 108)"
    },
    {
      "type": "F",
      "label": "F3",
      "text": "Words in reg. 179(2) substituted (31.12.2020) by S.I. 2019/775, reg. 139A(c) (as inserted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 108)"
    },
    {
      "type": "F",
      "label": "F4",
      "text": "Words in reg. 179(3)(a) substituted (31.12.2020) by S.I. 2019/775, reg. 139A(d) (as inserted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 108)"
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2012/1916/regulation/179",
    "retrieved_at": "2026-10-29T01:24:34.993203+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}